TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Smoking Behaviors While Using Varenicline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* self report minimum 10 daily cigarettes~* self report smoking every day past 5 years~* between the ages 21-65~* self report intention to try to quit smoking in the next 6 months~Exclusion Criteria:~* self reported use of any nicotine-containing products other than non-menthol cigarettes~* self reported history or current treatment of substance abuse (other than nicotine dependence)~* self reported alcohol use greater than 25 standard drinks per week;~* currently pregnant, planned pregnancy or lactating (females: negative urine pregnancy screen)~* self reported history or current diagnosis of any Axis 1 disorders except past depression~* self reported serious or unstable disease within past year~* self reported history of epilepsy or seizure disorder;~* self reported history or current diagnosis of COPD (chronic obstructive pulmonary disease), cardiovascular disease, heart attack, or uncontrolled hypertension~* self reported kidney function impairment~* any current or recent (30 day) use of: smoking cessation medications, anti-psychotics, anti-depressants, anti-anxiety, panic medications, stimulants or opiate-containing medications~* less than 5 years of daily smoking~* any medical condition or concomitant medication that could compromise participant safety or treatment~* provide a baseline carbon monoxide (CO) reading \< 10 ppm~* self reported use of non filtered cigarettes~* inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Varenicline before placebo (Type: EXPERIMENTAL): Drug (Varenicline (Chantix)): Placebo~Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.
- Placebo then Varenicline (Type: EXPERIMENTAL): Placebo: Drug Varenicline (Chantix)~Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.~Intervention 'Drug (Varenicline (Chantix)): Placebo'

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of Parkinson's disease with a minimum duration of 1 year~* Presence of visual and/or auditory hallucinations, and/or delusions, occurring during the four weeks prior to study screening~* Psychotic symptoms must have developed after Parkinson's disease diagnosis was established~* Subject must be on stable dose of anti-Parkinson's medication for 1 month prior to Study Day 1 (Baseline) and during the trial~* Subject that has received stereotaxic surgery for subthalamic nucleus deep brain stimulation must be at least 6 months post surgery and the stimulator settings must have been stable for at least 1 month prior to Study Day 1 (Baseline) and must remain stable during the trial~* The subject is willing and able to provide consent~* Caregiver is willing and able to accompany the subject to all visits~Exclusion Criteria:~* Subject has a history of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia or bipolar disorder~* Subject has received previous ablative stereotaxic surgery (i.e., pallidotomy and thalamotomy) to treat Parkinson's disease~* Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder~* Subject has had a myocardial infarction in last six months~* Subject has any surgery planned during the screening, treatment or follow-up periods~Patients will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of psychosis severity, delirium, dementia, cardiovascular condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all protocol-specified entry criteria).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): pimavanserin tartrate (ACP-103) 20 mg, tablet, once daily by mouth, 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet, once daily by mouth, 6 weeks
- 1 (Type: EXPERIMENTAL): pimavanserin tartrate (ACP-103) 10 mg, tablet, once daily by mouth, 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Sulphadoxine-Pyrimethamine Use At Scale on Newborn Outcomes in Nigeria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must be pregnant.~2. Pregnant participants must have experienced quickening in course of gestation.~3. Participants must reside in an intervention or a counterfactual LGA.~Exclusion Criteria:~1. Non-pregnant residents in a counterfactual or an intervention LGA.~2. Non-residents of counterfactual or intervention LGA.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Community distribution of SP (Type: EXPERIMENTAL): All the eligible pregnant women were reached with SP either at health clinic and/or at community/household level with sulphadoxine-pyrimethamine (SP). Alerts and reminders were sent to them by community-based health volunteers ahead of subsequent SP doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures.~* Female or male aged =18 years and =70 years.~* Acute upper gastrointestinal bleeding (haematemesis, melaena or haematochezia) or such signs within the last 24 hours as judged by the investigator.~* One endoscopically confirmed bleeding gastric or duodenal peptic ulcer, at least 5 mm in diameter, classified as Forrest Ia, Ib, IIa, or IIb. Photo documentation of the source of bleeding should be provided.~* Successful haemostasis (which is considered to have been established if bleeding has stopped and, if applicable, formerly bleeding vessels are flattened or cavitated) achieved by endoscopic treatment and confirmed by site staff.~Exclusion Criteria:~* Endoscopic suspicion of gastric malignancy or juxta pyloric stenosis as judged by the investigator.~* Sign of multi PUB or concomitant other gastro bleeding from esophageal varices, reflux esophagitis, gastritis, Mallory Weiss rifts, ulcus simplex, Dieulafoy's lesion, colon, small bowel, or ulcer distal to the stom in Billroth-resected patients.~* Need for treatment during the first 7 days of the study with NSAIDs, Cyclooxygenase-2 (COX-2) inhibitors, acetyl salicylic acid (ASA) (including low dose) or clopidogrel.~* Planned treatment with: warfarin (including other vitamin K antagonists), cisapride, phenytoin, atazanavir, nelfinavir, digoxin, methotrexate, clopidogrel, tacrolimus, theophylline, lidocaine, nifedipine.~* Chemotherapy or radiation therapies within 2 weeks prior to randomisation or planned during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Esomeprazole (Type: EXPERIMENTAL): None
- Cimetidine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endostapler Hemostasis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing planned laparoscopic sleeve gastrectomy with signed surgery consent form~* Informed consent for study obtained and signed from each subject~Exclusion Criteria:~* Planned open surgical approach~* Prior bariatric operation (i.e. revisional bariatric surgery)~* Use of staple line reinforcement material (buttress)~* Patients taking anticoagulants~* Patients under the age of 18 on the date of the surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AEON Endostapler (Type: None): Stapling performed by AEON Endostapler
- Echelon Flex Powered Stapler (Type: None): Stapling performed by Echelon Flex Powered Stapler

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable HF as defined by:~* No hospitalization for \>60 days~* Stable HF medications for \>=2 weeks, and stable diuretics for 4 weeks~* Opinion of HF cardiologist that the patient is at their optimal volume status~* Chronic daily oral loop diuretic dose \>=20mg furosemide equivalents~* Diagnosis of type II diabetes~* Patient monitors blood glucose regularly at home~* eGFR \>=45 mL/min/1.73 m2~* \>=18 years old~Exclusion Criteria:~* Active titration of chronic HF medications expected during the study period~* Use of a non-loop diuretic, aside from an aldosterone antagonist (\<=25mg spironolactone or \<=50mg eplerenone)~* Critical stenotic valvular disease, complex congenital heart disease, or prior heart transplant~* History of diabetic ketoacidosis, brittle diabetes, and/or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months~* History of bladder dysfunction, incontinence, pyelonephritis, urosepsis, or frequent urinary tract infections~* Anemia (defined as hemoglobin \<8g/dL)~* Pregnancy or breastfeeding~* History of serious hypersensitivity~* Participation in another trial with an investigational drug within the 30 days prior to informed consent~* Use of another SGLT-2 inhibitor~* Appears unlikely, or unable to participate in the required study procedures, as assessed by the study PI or research RN (ex: clinically-significant psychiatric, addictive, or neurological disease)~* Inability to give written informed consent or follow study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo, then empagliflozin (Type: EXPERIMENTAL): Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy.
- Empagliflozin, then Placebo (Type: EXPERIMENTAL): Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age≥18 years, ≤70 years, male or female;~* Advanced collecting duct carcinoma of the kidney is diagnosed histologically or pathologically ;~* Have not received anti-angiogenesis targeted drug therapy and systemic chemotherapy;~* Have at least one measurable tumor lesion (Response Evaluation Criteria In Solid Tumors);~* Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1;~* The expected life span is ≥12 weeks;~* No contraindications for chemotherapy, with enough liver function and renal function and normal ECG recording.Peripheral hemogram: neutrophil≥1.5×109/L, Plt≥100×109/L, Hgb≥90 g/L;Renal function: serum creatinine≤1.5 folds the upper limit of normal (ULN); For patients with non-metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤2.5 ULN, For patients with metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤5 ULN;~* The patients participate voluntarily and have signed the informed consent form.~Exclusion Criteria:~* Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures;~* Patients with severe acute infection without being controlled effectively or having pyogenic and chronic infections with persistently unhealed wounds;~* Past history of serious heart diseases, including: cardiac function classification ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled hypertension;~* Patients with a history of HIV infection or active phase of chronic hepatitis B/C;~* negative imaging examination result 4 weeks prior to enrollment);~* Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs);~* A history of allogeneic organ transplantation;~* Patients with evidence of hemorrhagic constitution or a past history of hemorrhage;~* Patients currently receiving renal dialysis;~* Past or present concomitant tumors with the primary lesions or histological characteristics different from the tumors evaluated in this study, excluding other tumor cured longer than 3 years before enrollment;~* Patients participating in other clinical trials simultaneously;~* Other conditions unsatisfying the inclusion criteria in the investigator's opinions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- sorafenib combined with chemotherapy (Type: EXPERIMENTAL): this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD according to GOLD criteria (FEV1/FVC\<70%), classification into GOLD I (FEV1 70-100% predicted), GOLD II (FEV1 50-70% predicted), GOLD III (FEV1 30- 50% predicted) or GOLD IV (FEV1 ≤ 30% predicted)~* Age ≥ 18 years~* Three or more exacerbations of COPD in one year for which a course of prednisone and/or antibiotic therapy was started~* Clinically stable during 1 month. Patients have to be free of COPD exacerbation or respiratory tract infection within a month prior to involvement in the study and they should not have received a high dose of systemic glucocorticoids or antibiotics in this period~* Informed consent~Exclusion Criteria:~* Use of antibiotics or high dose of systemic steroids within a month prior to involvement in the study.~* Addition of inhalation steroids to the patient's therapy regimen, shortly before entering the study.~* Pregnant or lactating women.~* Allergy to macrolides.~* Liver disease (alanine transaminase and/or aspartate transaminase levels 2 or more times the upper limit of normal).~* Asthma, defined as episodic symptoms of airflow obstruction which is reversible with bronchodilators, assessed with lung function testing.~* Presence of a malignancy which is clinically active.~* Bronchiectasis.~* Malignancy of any kind for which the subject is under treatment or is being monitored as part of follow up after treatment.~* Heart failure.~* Use of drugs which can adversely interact with macrolides and for which therapeutic monitoring cannot be undertaken.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: ACTIVE_COMPARATOR): Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in this group will receive 3 times a week placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating females age 12 and older.~* Clinical diagnosis of moderate to severe scalp psoriasis, defined by a Investigator's Global Assessment score of at least 3 at screening.~Exclusion Criteria:~* Under 12 years of age.~* Patients whose scalp and/or non-scalp psoriasis necessitates systemic or other concomitant topical therapies during the study.~* Has a scalp skin condition that would interfere with the diagnosis or assessment of plaque psoriasis of the scalp.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DSXS1411 (Type: EXPERIMENTAL): DSXS applied once a day for a total of 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (vehicle) applied once a day for a total of 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* As stated above~Exclusion Criteria:~* N/A

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- MyMenoPlan (Type: EXPERIMENTAL): Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
- Control (Type: ACTIVE_COMPARATOR): Participants are asked to spend at least 20 minutes on at least one of the following websites or other websites of their choice:~1. North American Menopause Society: https://www.menopause.org/for-women~2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 20 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960).~* Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study.~Exclusion Criteria:~* Patients with bipolar I or bipolar II disorder~* Patients with personality disorders~* Patients with eating disorders~* Patients with substance dependence or abuse~* Patients with concurrent active medical condition~* Patients with history of seizures~* Patients with history of receiving Electroconvulsive therapy (ECT)~* Patients with inflammatory disorders~* Patients with allergy or contraindications to the used medications~* Patients with finally pregnant or lactating females~* Cardiovascular disorders~* Severe renal impairment: creatinine clearance of ≤ 25 ml/min~* Moderate or severe hepatic impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Escitalopram 20 mg tablet once daily for 6 week plus placebo tablet twice daily for 6 weeks
- Cilostazol group (Type: EXPERIMENTAL): Escitalopram 20 mg tablet once daily for 6 week plus Cilostazol 50mg tablet twice daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete